Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism

Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. W G Ding , E Renström , P Rorsman , K Buschard and J Gromada Department of Islet Cell Physiology, Kommunehospitalet, Copenhagen, Denm...

Full description

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 46; no. 5; pp. 792 - 800
Main Authors Ding, W. G., Renstrom, E., Rorsman, P., Buschard, K., Gromada, J.
Format Journal Article
LanguageEnglish
Published American Diabetes Association 01.05.1997
Online AccessGet full text

Cover

Loading…
More Information
Summary:Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. W G Ding , E Renström , P Rorsman , K Buschard and J Gromada Department of Islet Cell Physiology, Kommunehospitalet, Copenhagen, Denmark. Abstract High-resolution capacitance measurements were used to explore the effects of the gut hormones GLP-I(7-36) amide [glucagon-like peptide I(7-36) amide] and GIP (glucose-dependent insulinotropic polypeptide) on Ca2+-dependent exocytosis in glucagon-secreting rat pancreatic alpha-cells. Both peptides produced a greater than threefold potentiation of secretion evoked by voltage-clamp depolarizations, an effect that was associated with an approximately 35% increase of the Ca2+ current. The stimulatory actions of GLP-I(7-36) amide and GIP were mimicked by forskolin and antagonized by the protein kinase A (PKA)-inhibitor Rp-8-Br-cAMPS. The islet hormone somatostatin inhibited the stimulatory action of GLP-I(7-36) amide and GIP via a cyclic AMP-independent mechanism, whereas insulin had no effect on exocytosis. These data suggest that the alpha-cells are equipped with receptors for GLP-I and GIP and that these peptides, in addition to their well-established insulinotropic capacity, also stimulate glucagon secretion. We propose that the reported inhibitory action of GLP-I on glucagon secretion is accounted for by a paracrine mechanism (e.g., mediated by stimulated release of somatostatin that in turn suppresses exocytosis in the alpha-cell).
ISSN:0012-1797
1939-327X
0012-1797
DOI:10.2337/diabetes.46.5.792